Novo Nordisk A/S (NYSE:NVO) Chief Executive Officer (CEO) Mike Doustdar said the company's obesity medicines may have uses beyond weight loss as researchers continue studying the broader effects of semaglutide.
"We have to be obsessed with what our patients want," Doustdar said Sunday in an interview with Bloomberg at the American Diabetes Association conference in New Orleans.
Novo Nordisk is a Danish drugmaker best known for Ozempic, a diabetes treatment, and Wegovy, a weight-loss medicine.
Both drugs contain semaglutide, one of the most closely watched compounds in the pharmaceutical industry.
Doustdar said the company is exploring whether future generations of GLP-1 medicines could be used to treat additional diseases beyond obesity and diabetes.
